Reviva Pharmaceuticals Holdings, Inc. - Common Stock (RVPH)

Competitors to Reviva Pharmaceuticals Holdings, Inc. - Common Stock (RVPH)

Axovant Gene Therapies Ltd.

Axovant focuses on developing innovative gene therapies for neurological diseases, which overlaps with some of Reviva's therapeutic areas. Both companies aim to advance treatments for unmet medical needs in neuroscience, leading to competition for funding, research talent, and clinical trial subjects. Axovant's established gene therapy platform could provide a competitive edge in terms of technology and market expertise.

Kamada Ltd. 

Kamada is a global biopharmaceutical company that develops and commercializes innovative therapies primarily for rare diseases, and they competently target specific clinical applications as does Reviva. However, Kamada's established products and revenue streams provide them with a more robust operational model, placing them at an advantage in terms of resources and development capabilities.

Neurocrine Biosciences, Inc. 

Neurocrine Biosciences is a biopharmaceutical company specializing in neurological and endocrine-related treatments. It competes with Reviva by developing novel approaches to chronic neurological disorders, leveraging a well-established commercial framework and existing successful product portfolio which gives Neurocrine a strong competitive advantage in market access and brand recognition compared to Reviva.

Ovid Therapeutics Inc. 

Ovid Therapeutics specializes in the development of therapies for neurological disorders, similar to Reviva's focus areas. The competition revolves around the effectiveness of their clinical trials and the ability to attract investment. While both companies pursue innovative treatments, Ovid's strategic partnerships and experience in clinical development may offer it a stronger foothold in the market.

Sorrento Therapeutics, Inc.

Sorrento Therapeutics operates in the biotechnology sector with a focus on developing therapies for various types of cancer and pain management, which are also areas of interest for Reviva. Both companies have ongoing projects targeting similar indications, but Sorrento's extensive pipeline and partnerships provide it with a broader market presence and potentially faster revenue generation, likely placing it ahead in competitive positioning.